Brokerage Firm Rating on TransEnterix (TRXC)

TransEnterix (TRXC) : The consensus on TransEnterix (TRXC) based on 5 analyst recommendation on the company stock is 1.6, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

TransEnterix (TRXC) : Currently there are 5 street experts covering TransEnterix (TRXC) stock. The most bullish and bearish price target for the stock is $4 and $2 respectively for the short term. The average price target of all the analysts comes to $3.25. The estimated standard deviation from the target is $0.79.


For the current week, the company shares have a recommendation consensus of Buy. TransEnterix (NYSEMKT:TRXC): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.52 and $1.35 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.52. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.41, notching a gain of 3.68% for the day. The total traded volume was 545,382 . The stock had closed at $1.36 on the previous day.

In a related news, Fernando Anthony C. J., officer (Chief Technology Officer) of Transenterix Inc. had purchased 27,000 shares on June 14, 2016 in a transaction. The price per share was $1.46 and the total amount of the disclosed transaction was $39,420.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.

TransEnterix, Inc. is a medical device company focused on the development and commercialization of a robotic assisted surgical system called the SurgiBot System (the SurgiBot System). The Companys SurgiBot System is designed to utilize flexible instruments through articulating channels controlled directly by the surgeon with robotic assistance while the surgeon remains patientside within the sterile field. It has commercialized the SPIDER Surgical System, (the SPIDER System) a manual laparoscopic system in the United States, Europe and the Middle East. The SPIDER System utilizes flexible instruments and articulating channels that are controlled directly by the surgeon, allowing for multiple instruments to be introduced through a single site. It also offers Flex Ligating Shears (FLS) which is an energy device used with the existing SPIDER Surgical System. The FLS device is designed to deliver controlled energy to ligate and divide tissue.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.